Search Results

The Efficacy and Safety of Udenafil [Zydena] for the Treatment of Erectile Dysfunction in Hypertensive Men Taking Concomitant Antihypertensive Agents

Authors: Paick, Jae-Seung; Kim, Sae Woong; Park, Yoon Kyu; Hyun, Jae Seog; Park, Nam Cheol; Lee, Sung Won; Park, Kwanjin; Moon, Ki Hak; Chung, Woo Sik

Source: The Journal of Sexual Medicine, Volume 6, Number 11, November 2009 , pp. 3166-3176(11)

Publisher: Blackwell Publishing

PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile

Authors: Kouvelas, D.; Goulas, A.; Papazisis, G.; Sardeli, C.; Pourzitaki, C.

Source: Current Pharmaceutical Design, Volume 15, Number 30, October 2009 , pp. 3464-3475(12)

Publisher: Bentham Science Publishers

Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction

Authors: Kim, Tae-Eun; Kim, Bo-Hyung; Kim, Jung-Ryul; Lim, Kyoung Soo; Hong, Jang Hee; Kim, Kyu-pyo; Kim, Hwa-Sook; Shin, Sang-Goo; Jang, In-Jin; Yu, Kyung-Sang

Source: British Journal of Clinical Pharmacology, Volume 68, Number 1, July 2009 , pp. 43-46(4)

Publisher: Blackwell Publishing

Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2

Authors: Kang, HE; Bae, SK; Yoo, M; Lee, DC; Kim, YG; Lee, MG

Source: British Journal of Pharmacology, Volume 156, Number 6, March 2009 , pp. 1009-1018(10)

Publisher: Blackwell Publishing

Udenafil launched in Russia.

Source: Inpharma, Volume 1, Number 1653, 2008-08-30 , pp. 23-23(1)

Publisher: Adis International

Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects

Authors: Kim, Bo-Hyung; Lim, Hyeong-Seok; Chung, Jae-Yong; Kim, Jung-Ryul; Lim, Kyoung Soo; Sohn, Dong-Ryul; Cho, Joo-Youn; Yu, Kyung-Sang; Shin, Sang-Goo; Paick, Jae-Seung; Jang, In-Jin

Source: British Journal of Clinical Pharmacology, Volume 65, Number 6, June 2008 , pp. 848-854(7)

Publisher: Blackwell Publishing

Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress

Authors: Gur, Serap; Sikka, Suresh C; Hellstrom, Wayne JG

Source: Expert Opinion on Investigational Drugs, Volume 17, Number 6, June 2008 , pp. 855-864(10)

Publisher: Informa Healthcare

The Efficacy and Safety of Udenafil, a New Selective Phosphodiesterase Type 5 Inhibitor, in Patients with Erectile Dysfunction

Authors: Paick, Jae-Seung; Kim, Sae Woong; Yang, Dae Yeol; Kim, Ja Jong; Lee, Sung Won; Ahn, Tai Young; Choi, Hyung Ki; Suh, Jun-Kyu; Kim, Sae Chul

Source: The Journal of Sexual Medicine, Volume 5, Number 4, April 2008 , pp. 946-953(8)

Publisher: Blackwell Publishing

Looking to the Future for Erectile Dysfunction Therapies

Authors: Hatzimouratidis, Konstantinos; Hatzichristou, Dimitrios G.

Source: Drugs, Volume 68, Number 2, 2008 , pp. 231-250(20)

Publisher: Adis International

Phosphodiesterase 5 inhibitors and erectile dysfunction

Authors: Sandner, Peter; Svenstrup, Niels; Tinel, Hanna; Haning, Helmut; Bischoff, Erwin

Source: Expert Opinion on Therapeutic Patents, Volume 18, Number 1, January 2008 , pp. 21-33(13)

Publisher: Informa Healthcare

Dong-A Pharmaceutical has received approval from the Korean Food and Drug Administration to market udenafil [Zydena] for erectile dysfunction

Source: Inpharma, Volume 1, Number 1517, 2005-12-10 , pp. 17-17(1)

Publisher: Adis International

Product Introductions

Source: Inpharma, Volume 1, Number 1517, 2005-12-10 , pp. 19-19(1)

Publisher: Adis International